Breun Maria, Monoranu Camelia M, Kessler Almuth F, Matthies Cordula, Löhr Mario, Hagemann Carsten, Schirbel Andreas, Rowe Steven P, Pomper Martin G, Buck Andreas K, Wester Hans-Jürgen, Ernestus Ralf-Ingo, Lapa Constantin
Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany.
Department of Neuropathology, University of Würzburg, Institute of Pathology, Würzburg, Germany.
Front Oncol. 2019 Jun 12;9:503. doi: 10.3389/fonc.2019.00503. eCollection 2019.
We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [Ga]Pentixafor. 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. [Ga]Pentixafor PET/CT was visually positive in all cases. SUV and SUV were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR and TBR were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Non-invasive imaging of CXCR4 expression using [Ga]Pentixafor PET/CT of VS is feasible and could prove useful for assessment of CXCR4 expression.
我们最近证实了前庭神经鞘瘤（VS）中CXCR4的过表达。本研究使用放射性标记的趋化因子配体[镓]喷替沙福，调查了VS的CXCR4导向正电子发射断层扫描/计算机断层扫描（PET/CT）成像的可行性。招募了4例患有6个主要诊断或预处理/观察到的VS患者。所有受试者在手术切除前均接受了[镓]喷替沙福PET/CT检查。对图像进行了视觉和半定量分析，以评估CXCR4表达，包括计算肿瘤与背景比值（TBR）。免疫组织化学作为3例患者的参考标准。[镓]喷替沙福PET/CT在所有病例中视觉上均为阳性。SUV和SUV分别为3.0±0.3和3.8±0.4，TBR和TBR分别为4.0±1.4和5.0±1.7。组织学分析证实肿瘤中存在CXCR4表达。使用[镓]喷替沙福PET/CT对VS的CXCR4表达进行无创成像可行，且可能对评估CXCR4表达有用。
